Booz Allen Disagrees With U.S. DoJ's Characterization Of Proposed EverWatch Deal

Booz Allen Hamilton Holding Corp. (BAH) said Thursday that it strongly disagreed with the U.S. Department of Justice's characterization of the proposed $440 million, approximately 500-person EverWatch Corp transaction.

Booz Allen believe the acquisition would bring together two companies with complementary capabilities to support its collective national security interests and would enhance competition overall in an industry that is highly competitive.

Booz Allen believes the transaction would deliver significant benefits to its government clients and it refutes any suggestion that the proposed transaction would harm government agencies or taxpayers.

On Wednesday, the Department of Justice filed a civil antitrust lawsuit to block Booz Allen's proposed acquisition of EverWatch.

The complaint, filed in the U.S. District Court for the District of Maryland, alleged that the merger agreement threatens imminent competition for a government contract to provide operational modeling and simulation services to the National Security Agency (NSA). Unless enjoined, the transaction would eliminate competition for the defense contract, leaving NSA to face a monopoly bidder.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT